Research graph
References from Type 1 segmental Darier disease unmasked by enfortumab vedotin. Local targets link to admitted publications; unresolved targets remain external evidence.
Darier disease: current insights and challenges in pathogenesis and management
10.1111/jdv.20448 · 2025 · External reference
Localized Darier's disease in a Blaschkoid distribution: two cases of phenotypic mosaicism and a review of mosaic Darier's disease
10.1111/j.1346-8138.2007.00379.x · 2007 · External reference
Cutaneous toxicity associated with Enfortumab vedotin: a real-word Study leveraging U.S. food and drug administration adverse event reporting System
10.3389/fonc.2021.801199 · 2022 · External reference
Enfortumab Vedotin–Associated toxic epidermal necrolysis-like toxic erythema of chemotherapy
10.1097/dad.0000000000002255 · 2022 · External reference
Characterization of cutaneous adverse events to enfortumab vedotin: a retrospective case-control study
10.1016/j.jdin.2022.10.004 · 2022 · External reference
Management of dermatologic events associated with the Nectin-4-directed antibody-drug conjugate Enfortumab Vedotin
10.1093/oncolo/oyac001 · 2022 · External reference
Clinical and histopathological characterization of enfortumab vedotin-associated cutaneous toxicities: a case series
10.1016/j.jdcr.2024.12.019 · 2024 · External reference
The diverse landscape of dermatologic toxicities of non-immune checkpoint inhibitor monoclonal antibody-based cancer therapy
10.1111/cup.14327 · 2023 · External reference
